Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
(2017) In Blood 129(5). p.553-560- Abstract
Hairy cell leukemia is an uncommon hematologic malignancy characterized by pancytopenia and marked susceptibility to infection. Tremendous progress in the management of patients with this disease has resulted in high response rates and improved survival, yet relapse and an appropriate approach to retreatment present continuing areas for research. The disease and its effective treatment are associated with immunosuppression. Because more patients are being treated with alternative programs, comparison of results will require general agreement on definitions of response, relapse, and methods of determining minimal residual disease. The development of internationally accepted, reproducible criteria is of paramount importance in evaluating... (More)
Hairy cell leukemia is an uncommon hematologic malignancy characterized by pancytopenia and marked susceptibility to infection. Tremendous progress in the management of patients with this disease has resulted in high response rates and improved survival, yet relapse and an appropriate approach to retreatment present continuing areas for research. The disease and its effective treatment are associated with immunosuppression. Because more patients are being treated with alternative programs, comparison of results will require general agreement on definitions of response, relapse, and methods of determining minimal residual disease. The development of internationally accepted, reproducible criteria is of paramount importance in evaluating and comparing clinical trials to provide optimal care. Despite the success achieved in managing these patients, continued participation in available clinical trials in the firstline and particularly in the relapse setting is highly recommended. The Hairy Cell Leukemia Foundation convened an international conference to provide common definitions and structure to guide current management. There is substantial opportunity for continued research in this disease. In addition to the importance of optimizing the prevention and management of the serious risk of infection, organized evaluations of minimal residual disease and treatment at relapse offer ample opportunities for clinical research. Finally, a scholarly evaluation of quality of life in the increasing number of survivors of this now manageable chronic illness merits further study. The development of consensus guidelines for this disease offers a framework for continued enhancement of the outcome for patients.
(Less)
- author
- organization
- publishing date
- 2017-02-02
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Blood
- volume
- 129
- issue
- 5
- pages
- 8 pages
- publisher
- American Society of Hematology
- external identifiers
-
- scopus:85015285314
- pmid:27903528
- wos:000397016100006
- ISSN
- 0006-4971
- DOI
- 10.1182/blood-2016-01-689422
- language
- English
- LU publication?
- yes
- id
- 6d631e38-4492-4c72-9a15-621759a2ffe4
- alternative location
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5290982/
- date added to LUP
- 2017-04-03 10:26:52
- date last changed
- 2024-05-13 09:46:36
@article{6d631e38-4492-4c72-9a15-621759a2ffe4,
abstract = {{<p>Hairy cell leukemia is an uncommon hematologic malignancy characterized by pancytopenia and marked susceptibility to infection. Tremendous progress in the management of patients with this disease has resulted in high response rates and improved survival, yet relapse and an appropriate approach to retreatment present continuing areas for research. The disease and its effective treatment are associated with immunosuppression. Because more patients are being treated with alternative programs, comparison of results will require general agreement on definitions of response, relapse, and methods of determining minimal residual disease. The development of internationally accepted, reproducible criteria is of paramount importance in evaluating and comparing clinical trials to provide optimal care. Despite the success achieved in managing these patients, continued participation in available clinical trials in the firstline and particularly in the relapse setting is highly recommended. The Hairy Cell Leukemia Foundation convened an international conference to provide common definitions and structure to guide current management. There is substantial opportunity for continued research in this disease. In addition to the importance of optimizing the prevention and management of the serious risk of infection, organized evaluations of minimal residual disease and treatment at relapse offer ample opportunities for clinical research. Finally, a scholarly evaluation of quality of life in the increasing number of survivors of this now manageable chronic illness merits further study. The development of consensus guidelines for this disease offers a framework for continued enhancement of the outcome for patients.</p>}},
author = {{Grever, Michael R. and Abdel-Wahab, Omar and Andritsos, Leslie A. and Banerji, Versha and Barrientos, Jacqueline and Blachly, James S. and Call, Timothy G. and Catovsky, Daniel and Dearden, Claire and Demeter, Judit and Else, Monica and Forconi, Francesco and Gozzetti, Alessandro and Ho, Anthony D and Johnston, James B. and Jones, Jeffrey and Juliusson, Gunnar and Kraut, Eric and Kreitman, Robert J. and Larratt, Loree and Lauria, Francesco and Lozanski, Gerard and Montserrat, Emili and Parikh, Sameer A. and Park, Jae-Hyun and Polliack, Aaron and Quest, Graeme R. and Rai, Kanti R. and Ravandi, Farhad and Robak, Tadeusz and Saven, Alan and Seymour, John F. and Tadmor, Tamar and Tallman, Martin S. and Tam, Constantine and Tiacci, Enrico and Troussard, Xavier and Zent, Clive S. and Zenz, Thorsten and Zinzani, Pier-Luigi and Falini, Brunangelo}},
issn = {{0006-4971}},
language = {{eng}},
month = {{02}},
number = {{5}},
pages = {{553--560}},
publisher = {{American Society of Hematology}},
series = {{Blood}},
title = {{Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia}},
url = {{http://dx.doi.org/10.1182/blood-2016-01-689422}},
doi = {{10.1182/blood-2016-01-689422}},
volume = {{129}},
year = {{2017}},
}